Citadel Advisors
HBIO icon

Citadel Advisors’s Harvard Bioscience HBIO Stock Holding History

Citadel Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,930
Closed -$12.9K – 13483
2025
Q4 		$12.9K Sell
1,930
-2,310
-54% -$13.7K ﹤0.01% 12411
2025
Q3 		$18.6K Sell
4,240
-3,740
-47% -$17.7K ﹤0.01% 12501
2025
Q2 		$35.4K Buy
7,980
+7,110
+817% +$29.7K ﹤0.01% 11925
2025
Q1 		$4.92K Buy
+870
New +$11.1K ﹤0.01% 13855
2024
Q4 		– Sell
-70
Closed -$1.88K – 14864
2024
Q3 		$1.88K Sell
70
-50
-42% -$1.47K ﹤0.01% 13797
2024
Q2 		$3.42K Sell
120
-280
-70% -$9.82K ﹤0.01% 13597
2024
Q1 		$17K Buy
+400
New +$18K ﹤0.01% 13119
2023
Q4 		– Sell
-1,000
Closed -$43K – 14682
2023
Q3 		$43K Sell
1,000
-320
-24% -$14.8K ﹤0.01% 11926
2023
Q2 		$72.5K Buy
1,320
+1,140
+633% +$62.6K ﹤0.01% 11351
2023
Q1 		$7.56K Buy
180
+170
+1,700% +$5.04K ﹤0.01% 13710
2022
Q4 		$277 Buy
+10
New +$246 ﹤0.01% 14703
2021
Q4 		– Sell
-1,090
Closed -$76K – 14191
2021
Q3 		$76K Buy
+1,090
New +$86.7K ﹤0.01% 13105

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's HBIO Position: Q1 2026 in Review

Citadel Advisors sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 4,299 shares — an estimated $28.8K sold.

Citadel Advisors first reported a position in HBIO in Q2 2013 and held it in 27 quarters. The position peaked at $537K in Q2 2022. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Citadel Advisors reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 4,299 Harvard Bioscience shares in Q1 2026, an estimated $28.8K.
  • Citadel Advisors first reported a position in Harvard Bioscience in Q2 2013 and held it in 27 quarters.
  • Citadel Advisors's Harvard Bioscience position peaked at $537K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.